ACADIA Pharmaceuticals 2018 Annual Report

ACADIA Pharmaceuticals' 2018 annual report highlights the company's performance as a biopharmaceutical focused on CNS disorders. The company grew NUPLAZID net sales to $233.8 million (79% increase), advanced pimavanserin in late-stage trials for dementia-related psychosis and major depressive disorder, and expanded its pipeline through a license agreement for trofinetide to treat Rett syndrome.